{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T06:55:47Z","timestamp":1775372147004,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.cbi.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T10:25:33Z","timestamp":1554546333000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine"],"prefix":"10.1016","volume":"306","author":[{"given":"Noriaki","family":"Ikemura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinatsu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norie","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2019.04.005_bib1","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1074\/jbc.271.7.3460","article-title":"Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart","volume":"271","author":"Wu","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2019.04.005_bib2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1124\/mol.51.6.931","article-title":"CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance","volume":"51","author":"Zeldin","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2019.04.005_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/FPC.0b013e32810f2e58","article-title":"Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues","volume":"17","author":"Bi\u00e8che","year":"2007","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.cbi.2019.04.005_bib4","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1158\/0008-5472.CAN-04-4173","article-title":"Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors","volume":"65","author":"Jiang","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2019.04.005_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1124\/jpet.110.174805","article-title":"Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth","volume":"336","author":"Chen","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2019.04.005_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095532","article-title":"Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance","volume":"9","author":"Narjoz","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2019.04.005_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2017.05.005","article-title":"Cytochrome P450-derived eicosanoids and heart function","volume":"179","author":"Jamieson","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2019.04.005_bib8","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.1158\/0008-5472.CAN-06-3643","article-title":"Cytochrome P450 epoxygenase promotes human cancer metastasis","volume":"67","author":"Jiang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2019.04.005_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1172\/JCI58128","article-title":"Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice","volume":"122","author":"Panigrahy","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cbi.2019.04.005_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/jpet.300.1.298","article-title":"Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes","volume":"300","author":"Hashizume","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2019.04.005_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1124\/dmd.30.11.1240","article-title":"Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole","volume":"30","author":"Matsumoto","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2019.04.005_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/03602532.2013.806537","article-title":"Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance","volume":"45","author":"Xu","year":"2013","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2019.04.005_bib13","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2019.04.005_bib14","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2019.04.005_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2019.04.005_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab. Dipos."},{"key":"10.1016\/j.cbi.2019.04.005_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/dmd.112.048264","article-title":"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors","volume":"41","author":"Ren","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2019.04.005_bib18","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1073\/pnas.1613246113","article-title":"Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain","volume":"113","author":"Sisignano","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cbi.2019.04.005_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.118.249557","article-title":"A specific probe substrate for evaluation of CYP4A11 activity in human tissue microsomes and a highly selective CYP4A11 inhibitor: luciferin-4A and epalrestat","volume":"366","author":"Yamaori","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2019.04.005_bib20","doi-asserted-by":"crossref","first-page":"10237","DOI":"10.1021\/bi700876a","article-title":"Unusual regioselectivity and active site topology of human cytochrome P450 2J2","volume":"46","author":"Lafite","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2019.04.005_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425255.2.4.629","article-title":"Luminogenic cytochrome P450 assays","volume":"2","author":"Cali","year":"2006","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.cbi.2019.04.005_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2016.03.005","article-title":"Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites","volume":"107","author":"Karkhanis","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2019.04.005_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.abb.2007.03.028","article-title":"Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2","volume":"464","author":"Lafite","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.cbi.2019.04.005_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bcp.2014.06.020","article-title":"Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo","volume":"91","author":"Kaspera","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2019.04.005_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1124\/dmd.117.075846","article-title":"Heme modification contributes to the mechanism-based inactivation of human cytochrome P450 2J2 by two terminal acetylenic compounds","volume":"45","author":"Lin","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2019.04.005_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/dmd.118.080903","article-title":"Formation of both heme and apoprotein adducts contributes to the mechanism-based inactivation of human CYP2J2 by 17\u03b1-ethynylestradiol","volume":"46","author":"Lin","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2019.04.005_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2017.02.017","article-title":"Inhibition and inactivation of human CYP2J2: implication in cardiac pathophysiology and opportunities in cancer therapy","volume":"135","author":"Karkhanis","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2019.04.005_bib28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s002280050706","article-title":"Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions","volume":"55","author":"Katoh","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2019.04.005_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.toxlet.2016.10.005","article-title":"Optical isomers of dihydropyridine calcium channel blockers display enantiospecific effects on the expression and enzyme activities of human xenobiotics-metabolizing cytochromes P450","volume":"262","author":"\u0160t\u011bp\u00e1nkov\u00e1","year":"2016","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cbi.2019.04.005_bib30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/molecules22111879","article-title":"Influence of amlodipine enantiomers on human microsomal cytochromes P450: stereoselective time-dependent inhibition of CYP3A enzyme activity","volume":"22","author":"Krasulova","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.cbi.2019.04.005_bib31","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.113.053389","article-title":"Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes","volume":"41","author":"Evangelista","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2019.04.005_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.fct.2014.04.020","article-title":"Potential of decursin to inhibit the human cytochrome P450 2J2 isoform","volume":"70","author":"Lee","year":"2014","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.cbi.2019.04.005_bib33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejphar.2015.07.047","article-title":"Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells","volume":"764","author":"Jeon","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cbi.2019.04.005_bib34","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1124\/dmd.115.064345","article-title":"Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner","volume":"43","author":"Lee","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2019.04.005_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1124\/dmd.117.075036","article-title":"LKY-047: first selective inhibitor of cytochrome P450 2J2","volume":"45","author":"Phuc","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2019.04.005_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.phymed.2016.12.001","article-title":"Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells","volume":"24","author":"Park","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cbi.2019.04.005_bib37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cbi.2018.04.011","article-title":"Inhibitory effects of Danshen components on CYP2C8 and CYP2J2","volume":"289","author":"Xu","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2019.04.005_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/jpet.109.152017","article-title":"Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo","volume":"329","author":"Chen","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2019.04.005_bib39","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1158\/0008-5472.CAN-04-3771","article-title":"Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis","volume":"65","author":"Leung","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2019.04.005_bib40","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.2741\/3116","article-title":"Expression of cytochrome P450 in non-small cell lung cancer","volume":"13","author":"Oyama","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.cbi.2019.04.005_bib41","first-page":"3026","article-title":"Tumor-specific expression of cytochrome P450 CYP1B1","volume":"57","author":"Murray","year":"1997","journal-title":"Cancer Res."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279719303631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279719303631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:52:46Z","timestamp":1757857966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279719303631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":41,"alternative-id":["S0009279719303631"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2019.04.005","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}